Publications by authors named "Michael Lark"

Claim this Profile
T
TRV0109101, a G Protein-Biased Agonist of the -Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic Administration.
Michael Koblish, Richard Carr, Edward R Siuda, David H Rominger, William Gowen-MacDonald, Michael W Lark

J Pharmacol Exp Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.
David G Soergel, Ruth Ann Subach, Nancy Burnham, Michael W Lark, Ian E James

Pain· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biased ligands at G-protein-coupled receptors: promise and progress.
Jonathan D Violin, Aimee L Crombie, David G Soergel, Michael W Lark

Trends Pharmacol Sci· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers.
David G Soergel, Ruth Ann Subach, Brian Sadler, John Connell, Alan S Marion, Michael W Lark

J Clin Pharmacol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GPCR biased ligands as novel heart failure therapeutics.
Jonathan D Violin, David G Soergel, Guido Boerrigter, John C Burnett, Michael W Lark

Trends Cardiovasc Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers.
David G Soergel, Ruth Ann Subach, Conrad L Cowan, Jonathan D Violin, Michael W Lark

J Clin Pharmacol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.
Scott M DeWire, Dennis S Yamashita, David H Rominger, Guodong Liu, Conrad L Cowan, Michael W Lark

J Pharmacol Exp Ther· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.
Guido Boerrigter, David G Soergel, Jonathan D Violin, Michael W Lark, John C Burnett

Circ Heart Fail· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure.
Guido Boerrigter, Michael W Lark, Erin J Whalen, David G Soergel, Jonathan D Violin

Circ Heart Fail· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.
Jonathan D Violin, Scott M DeWire, Dennis Yamashita, David H Rominger, Lisa Nguyen, Michael W Lark

J Pharmacol Exp Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage.
Yihong Sui, Jennifer H Lee, Michael A DiMicco, Eric J Vanderploeg, Simon M Blake, Michael W Lark

Arthritis Rheum· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human articular chondrocytes produce IL-7 and respond to IL-7 with increased production of matrix metalloproteinase-13.
David Long, Simon Blake, Xiao-Yu Song, Michael Lark, Richard F Loeser

Arthritis Res Ther· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model.
Dora M Berman, Over Cabrera, Norman M Kenyon, Joshua Miller, Susan H Tam, Michael Lark

Transplantation· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
Dennis S Yamashita, Robert W Marquis, Ren Xie, Sirishkumar D Nidamarthy, Hye-Ja Oh, Michael W Lark

J Med Chem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azepanone-based inhibitors of human cathepsin L.
Robert W Marquis, Ian James, Jin Zeng, Robert E Lee Trout, Scott Thompson, Michael A Lark

J Med Chem· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms and kinetics of glycosaminoglycan release following in vitro cartilage injury.
Michael A DiMicco, Parth Patwari, Patrick N Siparsky, Sanjay Kumar, Michael A Pratta, Michael W Lark

Arthritis Rheum· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.
Robert W Marquis, Keith W Ward, Theresa Roethke, Brian R Smith, Yu Ru, Michael W Lark

Mol Pharm· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokines.
Parth Patwari, Michael N Cook, Michael A DiMicco, Simon M Blake, Ian E James, Michael W Lark

Arthritis Rheum· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
William H Miller, Peter J Manley, Russell D Cousins, Karl F Erhard, Dirk A Heerding, Michael W Lark

Bioorg Med Chem Lett· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist.
Sandra J Hoffman, Janice Vasko-Moser, William H Miller, Michael W Lark, Maxine Gowen

J Pharmacol Exp Ther· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel bone antiresorptive approaches.
Michael W Lark, Ian E James

Curr Opin Pharmacol· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Michael W Lark, G B Stroup, I E James, R A Dodds, S M Hwang

Bone· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis